Atossa Therapeutics Announces Publication of KARISMA Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal Women
Go back to Atossa Therapeutics Announces Publication of KARISMA Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal Women| ATOSSA GNTCS (NASDAQ: ATOS) | Delayed: 1.80 -0.03 (1.64%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.83 | 52 Week High | $3.64 | |||
| Open | $1.82 | 52 Week Low | $0.14 | |||
| Day High | $1.96 | P/E | N/A | |||
| Day Low | $1.78 | EPS | $0.00 | |||
| Volume | 369,463 | |||||
